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No net renal extraction of homocysteine in fasting humans.
Background. The pathophysiological mechanism of hyperhomocysteine-
mia in chronic renal failure in humans is unknown. The loss of a putative
renal homocysteine extraction in chronic renal failure has been hypothe-
sized as significant homocysteine uptake has been demonstrated in the
normal rat kidney. We studied homocysteine extraction in the normal
human kidney.
Methods. We measured plasma total (free and protein-bound) and free
homocysteine (tHcy and fHcy, respectively) in arterial and renal venous
blood sampled from the aorta and right-side renal vein during cardiac
catheterization in 20 fasting patients with normal renal function. Renal
homocysteine extraction was calculated as the arteriovenous difference
divided by the arterial level times 100%.
Results. No significant renal extraction was demonstrated either for
tHcy: 0.9% (SD 5.8; 95% CI 21.8 to 13.6) or for fHcy: 20.2% (11.0; 25.4
to 14.9).
Conclusions. We conclude that no significant net renal uptake of
homocysteine occurs in fasting humans with normal renal function. The
loss of such uptake, therefore, cannot cause hyperhomocysteinemia in
patients with renal failure.
Hyperhomocysteinemia is reported in 85 to 100% of
patients with end-stage renal disease (ESRD) [1, 2]. This is
an important finding as elevated plasma homocysteine
levels have been shown to be an independent atherothrom-
botic risk factor not only in the general population [3], but
also in ESRD patients [4]. The exact pathophysiological
mechanism of hyperhomocysteinemia in chronic renal fail-
ure is obscure.
Normally, only minimal amounts of homocysteine (3 to
10 mmol/24 hr) are found in the urine [5]. Loss of this
excretion, therefore, does not explain the high homocys-
teine levels in ESRD. Plasma homocysteine is negatively
correlated with renal function [6, 7], suggesting that pro-
gressive decline in renal function is accompanied by an
increase of the impairment in homocysteine metabolism.
An attractive explanation for these observations would be
the progressive loss of putative homocysteine clearance
within the kidney, either by decreased transsulfuration or
by decreased remethylation. Experimental evidence for the
existence of a net homocysteine uptake in the normal
kidney has been reported by Bostom et al, who demon-
strated considerable homocysteine uptake in the normal
postabsorptive-state rat kidney (N 5 6) by the finding of a
significant difference (;20%) in plasma total homocysteine
levels between arterial and renal venous blood [8]. By
extrapolating these data, it was suggested that renal uptake
and metabolism could account for about 70% of daily
homocysteine plasma elimination in humans, and that
hyperhomocysteinemia in chronic renal failure could
mainly be due to loss of this metabolism [9].
Human renal amino acid metabolism was studied by
Tizianello et al, using the arteriovenous difference tech-
nique [10]. Homocysteine, however, was not measured.
In the present study, we measured not only the total
homocysteine (tHcy), but also free (that is, filterable)
homocysteine (fHcy) and other amino acids in arterial and
renal venous blood of 20 patients with normal renal
function.
METHODS
Twenty patients (13 men) with normal renal function, aged
63.8 6 10.7 (SD) years, undergoing elective cardiac cathe-
terization for the assessment of coronary artery disease,
participated in the study. Patients were in the fasting state.
After being informed about the nature, purpose and risks
of the procedure, all patients gave their voluntary consent.
One catheter was inserted into the abdominal aorta and a
second catheter was placed in the right renal vein under
fluoroscopic control; its position was verified by an oxygen
saturation of the blood of . 80%. The right-sided renal
vein was chosen to avoid sampling blood from the vena
testicularis or ovarica. Blood samples were simultaneously
drawn from these catheters and put on ice. Plasma samples
were immediately centrifuged and half of the aliquots were
subsequently deproteinized with trichloroacetic acid.
Plasma was then stored at 220°C until analysis. Plasma
tHcy and fHcy were measured by HPLC with fluorescence
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detection. Tri-n-butyl-phosphine was used as the reducing
agent, and ammonium 7-fluorobenzo-2-oxa-1,3-diazole-4-
sulfonate as the thiol-specific fluorogenic reagent. Other
amino acid analyses were performed by HPLC after pre-
column derivatization with ortho-phthalaldehyde. All as-
says were done in one run. The intraassay coefficient of
variation of homocysteine determination was 2% in our
laboratory. Serum creatinine was measured by a modified
Jaffe´ reaction.
The renal extraction (RE) was calculated from the
concentrations in the aorta (A) and the renal vein (V)
according to the formula: RE 5 (A-V) z 100%/A.
RE was considered significant if the 95% confidence
interval did not include zero.
RESULTS
Renal extractions of creatinine and the amino acids are
shown in Table 1. There was no significant extraction of
either tHcy or fHcy. The ratio of fHcy/tHcy (SD) was 29.5%
(8.3) in arterial and 29.8% (8.5) in venous plasma. Citrul-
line was significantly extracted by the kidney and net renal
release was found for alanine, arginine, asparagine, histi-
dine, leucine, lysine, methionine, serine, threonine, trypto-
phan and tyrosine (Table 1).
DISCUSSION
Hyperhomocysteinemia occurs in ESRD and can be
treated with folic acid containing regimens [2, 11–13]. Thus
far, however, none of these therapies has been able to
completely normalize plasma homocysteine. This may ex-
plain our observations that long-term folic acid treatment
did not improve endothelial dysfunction in chronic hemo-
dialysis patients [2]. To optimize homocysteine-lowering
treatment in ESRD, elucidation of the defects in homocys-
teine metabolism in renal failure is required.
Loss of a renal homocysteine elimination capacity, which
is not compensated by an increase in extrarenal clearance,
has been implicated in the genesis of hyperhomocysteine-
mia in renal failure. This theory is mainly based on the
observation that considerable homocysteine uptake takes
place the rat kidney [8]. Our data, however, show that
under fasting conditions no net renal homocysteine uptake
occurs in humans.
In a preliminary study, we did not find a renal arterio-
venous difference in plasma homocysteine, but the low
number of patients (N 5 7) and the measurement of only
total (that is, free and protein-bound) homocysteine (tHcy)
limited the power to detect small differences [14]. The
present study confirms the finding of an absent renal tHcy
extraction and, in addition, fails to detect a significant renal
clearance of fHcy.
If it is assumed that only filtered homocysteine (fHcy) is
metabolized by the kidney, the arteriovenous difference in
tHcy (or in fHcy) in our study would have been 3.2 z 0.2
(that is, fHcy level z normal reference for filtration fraction)
5 0.64 mmol/liter. If one assumes that fHcy is completely






(%) SD 95% CI
Creatinine 90.5 15.6 75.7 13.6 16.4 3.3 14.9–17.9
tHcy 10.8 3.1 10.7 3.1 0.9 5.8 21.8–3.6
fHcy 3.2 1.6 3.2 1.4 20.2 11.0 25.4–4.9
Alanine 270.2 72.3 302.6 75.8 212.8 5.4 215.3–210.2
Arginine 79.0 13.6 91.7 14.0 216.6 5.6 219.2–214.0
Asparagine 35.9 6.9 38.8 6.6 28.8 4.7 210.9–26.6
Citrulline 32.9 7.3 21.0 7.1 36.3 12.0 30.7–42.0
Glutamine 488.2 67.8 477.6 73.7 2.2 4.9 20.1–4.5
Glutamate 100.9 31.8 97.9 25.7 0.0 17.2 28.0–8.1
Glycine 166.0 33.5 162.1 30.9 1.9 5.6 20.7–4.5
Histidine 67.0 7.6 69.9 7.6 24.5 4.6 26.7–22.4
Isoeucine 61.7 14.4 62.2 14.7 20.9 4.4 22.9–1.2
Leucine 108.2 24.4 111.9 25.2 23.5 3.5 25.2–21.9
Lysine 132.2 27.1 139.0 28.5 25.3 6.2 28.2–22.4
Methionine 16.8 4.9 17.8 5.5 25.9 8.3 29.7–22.0
Ornithine 46.5 19.2 47.0 18.0 22.9 13.7 29.4–3.5
Phenylalaine 51.1 4.6 51.4 15.1 20.5 4.1 22.4–1.4
Serine 87.7 18.6 127.3 28.6 245.6 15.9 253.9–238.1
Taurine 57.9 34.4 52.2 25.2 1.1 29.2 212.6–14.8
Threonine 102.4 30.4 109.9 33.5 27.4 4.5 29.5–25.3
Tryptophan 36.4 7.3 37.7 7.7 23.6 4.0 25.5–21.7
Tyrosine 57.4 12.5 65.1 12.3 214.3 7.4 217.8–210.9
Valine 216.0 45.0 211.1 62.0 1.9 22.2 28.5–12.3
Abbreviations are A, arterial concentration; SD, standard deviation; V, renal vein concentration; RE, renal extraction (calculated as (A-V)* 100/A;
negative extraction indicates generation); CI, confidence interval; tHcy, total homocysteine; fHcy, free (filterable) homocysteine. Significant REs are in
bold typeface.
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removed from plasma by glomerular filtration and tubular
absorption from peritubular capillaries, the difference
would have been 3.2 mmol/liter. Our study had a power of
95% (at a 5 0.05) to detect an arteriovenous difference in
plasma tHcy and fHcy level of 0.43 and 0.38 mmol/liter,
respectively.
Although serum creatinine level was normal in all pa-
tients, slight alterations in renal function may have been
present due to diffuse atherosclerotic disease and/or med-
ication (low dose aspirin and b-blockers). Our data, there-
fore, relate to a normal to a mildly impaired renal function.
The arterial levels and arteriovenous differences of the
other amino acids in our study are similar to those found by
Tizianello et al [10] and Tessari et al [15]. Data on
asparagine and tryptophan were not reported in those
studies, but we found a renal release of both amino acids.
We confirmed the finding of a substantial renal extraction
of citrulline and synthesis of arginine and serine. In con-
trast to Tizianello et al, who found no significant arterio-
venous difference of methionine [10], there was a small, but
significant, renal generation of methionine, the precursor
of homocysteine. As the homocysteine level did not change,
it is probable that the increase in methionine was caused by
renal protein breakdown [15].
Renal extraction of creatinine was slightly lower than
20% because the Jaffe´ method was used. In serum, a
heterogeneous group of substances, named “chromogens,”
interfere with the colorimetric Jaffe´ reaction. As these
chromogens are not extracted by the kidney, this results in
a reduction of the RE of creatinine [16].
It should be emphasized that the fact that we did not find
a renal arteriovenous difference in plasma homocysteine
does not exclude a renal homocysteine metabolism. It
merely reflects that no net metabolism occurs, either by an
absence of metabolism or by an equilibrium between
synthesis and breakdown. Previous in vitro and in vivo
research has shown that homocystine (that is, the oxidized
dimer of homocysteine) is reabsorbed by tubular cells using
a transport system shared with lysine, arginine, alpha-
aminoisobutyric acid and cystine [17–19]. In vitro studies
have also demonstrated that all homocysteine metabolizing
enzymes are present in kidney tissue [20–23]. However,
these data do not indicate whether and to what extent
homocysteine is metabolized by the kidney in vivo.
It is unknown whether significant renal uptake occurs in
patients with plasma homocysteine levels that are higher
than in our patients. Hyperhomocysteinemia can be
present in subjects with normal renal function, such as, in
patients with vitamin deficiencies or genetic defects in
homocysteine metabolism. If the kidneys play an active role
in homocysteine breakdown in such patients, it is appar-
ently not sufficient to normalize their plasma homocysteine
level. Renal dysfunction might aggravate (but not cause)
hyperhomocysteinemia in these patients.
Whether homocysteine uptake occurs under non-fasting
conditions is also unknown. Theoretically, renal homocys-
teine uptake might occur only after meals when plasma
homocysteine levels increase. Loss of such a postprandial
elimination capacity might contribute to hyperhomocys-
teinemia in renal failure. As homocysteine is not present in
food, the effect of meals on postprandial homocysteine
levels are likely mediated by hepatic protein and amino
acid metabolism. Elevations of plasma homocysteine levels
after meals have been described [24], but not consistently
[25], and in peritoneal dialysis patients we found stable
plasma homocysteine levels throughout the day [12]. Post-
prandial increases in plasma homocysteine level are likely
to be small and it seems unlikely that only (non-urinary)
renal metabolism is responsible for the return from post-
prandial to baseline levels.
Alternative mechanisms for hyperhomocysteinemia in
renal failure may be that, in ESRD, the kidneys produce
homocysteine or that renal protein breakdown is enhanced
and that the excess of released methionine is converted into
homocysteine in the liver. One might also speculate that
extrarenal homocysteine metabolism is impaired by factors
related to uremia per se such as accumulation of uremic
toxins, which could inhibit homocysteine metabolizing en-
zymes, interfere with the metabolism of folic acid [26], or
impair folic acid transmembrane transport [27]. The major
candidate site for extarenal homocysteine metabolism is
the liver, in which extensive amino acid and protein metab-
olism takes place, and in which many abnormalities of
amino acid metabolism have been described in renal fail-
ure, including those of sulfur-containing amino acids [28,
29].
Recently, Guttormsen et al have demonstrated a de-
creased plasma homocysteine elimination after peroral
homocysteine loading in eight non-fasting patients with
chronic renal failure [30]. It was calculated that tHcy
clearance was reduced by 70% in these patients [30], which
would be compatible with the theory of a lost renal capacity
to metabolize homocysteine [9]. A causal relation between
the decreased plasma tHcy clearance and a decreased renal
tHcy clearance, however, was not established, and the
results are also compatible with an impaired extrarenal
clearance.
We conclude that no significant net renal uptake of
homocysteine occurs in fasting man and suggest that hy-
perhomocysteinemia in renal failure is more likely caused
by an impairment in extrarenal metabolism.
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